MLTX (MoonLake Immunotherapeutics) Buyback Yield %: -0.36 (As of Jun. 30, 2026)


MLTX MoonLake Immunotherapeutics MLTX
31 GF Score
Price $19.47
! 3 Warning Signs
View Full Analysis

What is MoonLake Immunotherapeutics Buyback Yield %?

MoonLake Immunotherapeutics MLTX -2.26% 31 Buyback Yield % is -0.36 as of Jun. 30, 2026. GuruFocus rates MLTX with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 742 Biotechnology companies, MoonLake Immunotherapeutics ranks better than 76.42% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

MoonLake Immunotherapeutics's current buyback yield was -0.36%.

MoonLake Immunotherapeutics Buyback Yield % Related Terms

MoonLake Immunotherapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for MoonLake Immunotherapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MoonLake Immunotherapeutics Buyback Yield % Chart

MoonLake Immunotherapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
0.00 0.00 -13.21 -1.54 -7.70

MoonLake Immunotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -7.70 -0.45

MLTX vs FTRE, SEPN, URGN: Buyback Yield % Comparison

For the Biotechnology subindustry, MoonLake Immunotherapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MoonLake Immunotherapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MoonLake Immunotherapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where MoonLake Immunotherapeutics's Buyback Yield % falls into.


MLTX
31GF Score
MoonLake Immunotherapeutics MLTX
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MoonLake Immunotherapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

MoonLake Immunotherapeutics's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 72.395) / 940.70932
=-7.70%

MoonLake Immunotherapeutics's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 6.007) / 1344.57776
=-0.45%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -0.36 mean?
MoonLake Immunotherapeutics (MLTX) has a Buyback Yield % of -0.36 as of Jun. 30, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on MoonLake Immunotherapeutics and its competitors. According to the industry distribution chart, MoonLake Immunotherapeutics ranks #175 out of 742 companies in the Biotechnology industry, placing it in the top 23.6%.
Is MoonLake Immunotherapeutics' Buyback Yield % too high?
MoonLake Immunotherapeutics' current Buyback Yield % is -0.36. Based on the distribution chart, MoonLake Immunotherapeutics ranks #175 out of 742 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, MoonLake Immunotherapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does MoonLake Immunotherapeutics' Buyback Yield % compare to FTRE and SEPN?
According to the Biotechnology industry distribution chart, MoonLake Immunotherapeutics ranks #175 out of 742 companies for Buyback Yield %. This places MoonLake Immunotherapeutics in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on MoonLake Immunotherapeutics and its competitors. MoonLake Immunotherapeutics's current Buyback Yield % is -0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MoonLake Immunotherapeutics stock overvalued right now?
MoonLake Immunotherapeutics (MLTX) has a current Buyback Yield % of -0.36. The current Buyback Yield % is -0.36. MoonLake Immunotherapeutics' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For MoonLake Immunotherapeutics (MLTX), the current Buyback Yield % is -0.36 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MoonLake Immunotherapeutics Business Description

Address Dorfstrasse 29, Zug, CHE, 6300
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
31GF Score

Get the complete analysis for MLTX

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.47
Price